

L1 0 S US 20060210624/PN  
L2 0 S US 20060210624/PN

FILE 'REGISTRY' ENTERED AT 15:32:38 ON 05 JUL 2009  
E OLANZAPINE/RN  
E OLANZAPINE/CN  
SET EXPAND CONTINUOUS

L3 1 S E3  
E BF2649/CN  
E BF 2649/CN

L4 1 S E27  
E RISPERIDONE/CN

L5 1 S E39  
E ARIPIPRAZOLE/CN

L6 1 S E51

FILE 'CAPLUS' ENTERED AT 15:35:35 ON 05 JUL 2009

L7 1 S L3 AND L4  
L8 1452 S L3 AND (L5 OR L6)  
L9 357 S L8 AND (PY<2003 OR AY<2003 OR PRY<2003)  
L10 245 S L8 AND (SIDE EFFECT?)  
L11 231 S L10 AND (?PSYCHOTIC? OR ?DEPRESSANT?)  
L12 67 S L11 AND (APPETITE? OR WEIGHT?)  
L13 11 S L12 AND (PY<2003 OR AY<2003 OR PRY<2003)  
L14 1 S L4 AND (L5 OR L6)  
L15 2 S L4 AND (?DEPRESSANT? OR ?PSYCHOTIC? OR NEUROLEPTIC?)  
L16 2 S L4 AND (ANTIDEPRESSANT? OR ANTIPSYCHOTIC?)  
L17 0 S L16 AND (PY<2003 OR AY<2003 OR PRY<2003)  
L18 0 S L4 AND (WEIGHT (L) GAIN?)  
L19 1 S L4 AND (APPETITE? OR WEIGHT?)  
L20 1 S L4 AND (OBES? OR OVERWEIGHT?)  
L21 0 S L20 NOT L19  
L22 3 S L4 AND (COGNIT?)  
L23 0 S L22 AND (PY<2003 OR AY<2003 OR PRY<2003)  
L24 2 S L4 AND (?ANXIETY OR ?ANXIO? OR ?PSYCH?)  
L25 0 S L24 AND (PY<2003 OR AY<2003 OR PRY<2003)  
L26 0 S L4 AND (?EMOTION? OR NEUROLOGIC?)  
L27 5 S L4  
L28 0 S L4 AND (PY<2003 OR AY<2003 OR PRY<2003)  
L29 0 S L4 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'REGISTRY' ENTERED AT 15:50:35 ON 05 JUL 2009  
E CIPROXIDINE/CN

L30 1 S E63

E BF 2649/CN  
SET EXPAND CONTINUOUS

L1 1 S E3  
L2 STRUCTURE UPLOADED  
L3 1425 S L2 SSS FULL

FILE 'CAPLUS' ENTERED AT 07:53:22 ON 06 JUL 2009

L4 170 S L3  
L5 10 S L3 AND HISTAMINE?  
L6 8 S L5 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'REGISTRY' ENTERED AT 07:55:44 ON 06 JUL 2009

		E 1129260-21-4/RN
L7	1 S E15	E 1129275-24-6/RN
L8	1 S E27	E 1129247-23-9/RN
L9	1 S E39	E 1129266-95-0/RN
L10	1 S E51	E 1129303-48-5/RN
L11	1 S E63	E 1129304-94-9/RN
		E 1129304-59-1/RN
L12	1 S E87	E 1129247-84-2/RN
L13	1 S E99	E 1129305-30-1/RN
L14	1 S E111	

FILE 'CAPLUS' ENTERED AT 08:02:46 ON 06 JUL 2009  
 L15 1 S WO 2005000315/PN

L15 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN  
 TI New psychiatric drug formulation with an antipsychotic or  
 antidepressant  
 and an histamine H3 receptor antagonist for the prevention of  
 psychotropic  
 adverse effects  
 ACCESSION NUMBER: 2005:589 CAPLUS Full-text  
 DOCUMENT NUMBER: 142:79960  
 TITLE: New psychiatric drug formulation with an  
 antipsychotic  
 or antidepressant and an histamine H3 receptor  
 antagonist for the prevention of psychotropic  
 adverse  
 effects  
 INVENTOR(S): Schwartz, Jean Charles; Rousseau Lecomte,  
 Jeanne Marie  
 PATENT ASSIGNEE(S): Bioprojet, Fr.  
 SOURCE: Fr. Demande, 32 pp.  
 CODEN: FRXXBL  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
---				
FR 2856596 20030627	A1	20041231	FR 2003-7836	
FR 2856596 CA 2530381 20040625	B1 A1	20070427 20050106	CA 2004-2530381	
WO 2005000315 20040625 <-- CH,	A1	20050106	WO 2004-FR1628	


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA,

GD, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB,  
 LC, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,  
 NI, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,  
 SY, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,  
 ZW, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
 AM, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,  
 DK, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE,  
 SE, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO,  
 NE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
 SN, TD, TG  
 EP 1641461 A1 20060405 EP 2004-767475  
 20040625  
 PT, R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,  
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK  
 JP 2007516160 T 20070621 JP 2006-516331  
 20040625 MX 2005013877 A 20060313 MX 2005-13877  
 20051216 US 20060210624 A1 20060921 US 2005-562396  
 20051227  
 PRIORITY APPLN. INFO.: FR 2003-7836 A  
 20030627 WO 2004-FR1628 W  
 20040625

FILE 'REGISTRY' ENTERED AT 08:03:23 ON 06 JUL 2009  
 L16 1 S 5786-21-0/RN

L16 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN  
 RN 5786-21-0 REGISTRY  
 CN 5H-Dibenzo[b,e][1,4]diazepine, 8-chloro-11-(4-methyl-1-piperazinyl)-(CA  
 INDEX NAME)  
 OTHER NAMES:  
 CN 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine  
 CN Asaleptin  
 CN Azaleptine  
 CN Cloril  
 CN Clozapin  
 CN Clozapine  
 CN Clozaril  
 CN Fazaclo  
 CN HF 1854  
 CN Iprox  
 CN Klozapol

CN Leponex  
 MF C18 H19 Cl N4  
 CI COM  
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*,  
 BIOSIS,  
 BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN,  
 CSCHEM,  
 DDFU, DRUGU, EMBASE, HSDB\*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH,  
 IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE,  
 MRCK\*,  
 PHAR, PROMT, PS, RTECS\*, SPECINFO, SYNTHLINE, TOXCENTER, USAN,  
 USPAT2,  
 USPATFULL  
 (\*File contains numerically searchable property data)  
 Other Sources: EINECS\*\*, WHO  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)  
 DT.CA CAplus document type: Book; Conference; Dissertation; Journal;  
 Patent;  
 Report  
 RL.P Roles from patents: ANST (Analytical study); BIOL (Biological  
 study);  
 PREP (Preparation); PROC (Process); PRP (Properties); PRPH  
 (Prophetic);  
 RACT (Reactant or reagent); USES (Uses)  
 RLD.P Roles for non-specific derivatives from patents: BIOL  
 (Biological  
 study); FORM (Formation, nonpreparative); PREP (Preparation);  
 PROC  
 (Process); PRP (Properties); USES (Uses)  
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL  
 (Biological  
 study); FORM (Formation, nonpreparative); MSC (Miscellaneous);  
 OCCU  
 (Occurrence); PREP (Preparation); PROC (Process); PRP  
 (Properties); RACT  
 (Reactant or reagent); USES (Uses)  
 RLD.NP Roles for non-specific derivatives from non-patents: ANST  
 (Analytical  
 study); BIOL (Biological study); FORM (Formation,  
 nonpreparative); PREP  
 (Preparation); PROC (Process); PRP (Properties); USES (Uses)




SET NOTICE 1 DISPLAY  
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 08:03:38 ON 06 JUL 2009  
L17 1 S 85650-52-8/RN

L17 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 85650-52-8 REGISTRY  
CN Pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine,  
1,2,3,4,10,14b-hexahydro-2-methyl- (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine,  
1,2,3,4,10,14b-hexahydro-2-methyl-, (±)-  
OTHER NAMES:  
CN 6-Azamianserin  
CN Avanza  
CN Mepirzapin  
CN Mepirzepine  
CN Mirtabene  
CN Mirtaz 15  
CN Mirtazapine  
CN Mirtazepine  
CN Mirtazipine  
CN Norset  
CN Org 3770  
CN Promyrtil  
CN Remergil  
CN Remergon  
CN Remeron  
CN Rexer  
CN Zispin  
DR 61337-67-5, 82601-27-2  
MF C17 H19 N3  
CI COM  
SR European Union (EU)  
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*,  
BIOSIS,  
BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN,  
CSCHEM,  
DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH,  
IMSDRUGNEWS,  
IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK\*, MSDS-  
OHS,  
PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS\*, SYNTHLINE, TOXCENTER,  
USAN,  
USPAT2, USPATFULL  
(\*File contains numerically searchable property data)  
Other Sources: EINECS\*\*, WHO  
(\*\*Enter CHEMLIST File for up-to-date regulatory information)  
DT.CA CAplus document type: Book; Conference; Dissertation; Journal;  
Patent;  
Report  
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological  
study);  
PREP (Preparation); PROC (Process); PRP (Properties); RACT  
(Reactant or  
reagent); USES (Uses); NORL (No role in record)  
RLD.P Roles for non-specific derivatives from patents: ANST  
(Analytical

study); BIOL (Biological study); PRP (Properties); USES (Uses)  
RL.NP Roles from non-patents: ANST (Analytical study); BIOL  
(Biological  
study); OCCU (Occurrence); PREP (Preparation); PROC (Process);  
PRP  
(Properties); RACT (Reactant or reagent); USES (Uses)  
RLD.NP Roles for non-specific derivatives from non-patents: BIOL  
(Biological  
study); PREP (Preparation)




SET NOTICE 1 DISPLAY  
SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 08:03:55 ON 06 JUL 2009  
L18 1 S 106266-06-2/RN

L18 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 106266-06-2 REGISTRY  
CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl- (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 1,2-Benzisoxazole, 4H-pyrido[1,2-a]pyrimidin-4-one deriv.  
OTHER NAMES:  
CN Apexidone  
CN Psychodal  
CN R 64766  
CN Rispadol  
CN Risperdal  
CN Risperdal Consta  
CN Risperidal  
CN Risperidone  
CN Spiron  
MF C23 H27 F N4 O2  
CI COM  
SR CA  
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*,  
BIOSIS,  
BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM,  
DDFU,  
DRUGU, EMBASE, HSDB\*, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS,  
IMSPRODUCT,  
IMSRESEARCH, IPA, MEDLINE, MRCK\*, PATDPASPC, PHAR, PROMT,  
PROUSDDR, PS,  
RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)

Other Sources: WHO  
 DT.CA Cplus document type: Book; Conference; Dissertation; Journal;  
 Patent  
 RL.P Roles from patents: ANST (Analytical study); BIOL (Biological  
 study);  
 PREP (Preparation); PROC (Process); PRP (Properties); PRPH  
 (Prophetic);  
 RACT (Reactant or reagent); USES (Uses)  
 RLD.P Roles for non-specific derivatives from patents: BIOL  
 (Biological  
 study); PREP (Preparation); PROC (Process); USES (Uses)  
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL  
 (Biological  
 study); MSC (Miscellaneous); NANO (Nanomaterial); OCCU  
 (Occurrence);  
 PREP (Preparation); PROC (Process); PRP (Properties); RACT  
 (Reactant or  
 reagent); USES (Uses)  
 RLD.NP Roles for non-specific derivatives from non-patents: BIOL  
 (Biological  
 study); PROC (Process); PRP (Properties); USES (Uses)




SET NOTICE 1 DISPLAY  
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 08:04:11 ON 06 JUL 2009  
 L19 1 S 111974-69-7/RN

L19 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN  
 RN 111974-69-7 REGISTRY  
 CN Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-  
 (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Dibenzo[b,f][1,4]thiazepine, ethanol deriv.  
 OTHER NAMES:  
 CN Quetiapine  
 DR 264256-90-8  
 MF C21 H25 N3 O2 S  
 CI COM  
 SR CA  
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, CA,  
 CAPLUS,  
 CASREACT, CBNB, CHEMCATS, CIN, DDFU, DRUGU, HSDB\*, IMSDRUGNEWS,  
 IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MRCK\*, PATDPASPC, PHAR,  
 PROMT,  
 PROUSDDR, PS, RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2,


USPATFULL  
(\*File contains numerically searchable property data)  
DT.CA Cplus document type: Book; Conference; Dissertation; Journal;  
Patent  
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological  
study);  
FORM (Formation, nonpreparative); PREP (Preparation); PROC  
(Process);  
PRP (Properties); PRPH (Prophetic); RACT (Reactant or reagent);  
USES  
(Uses)  
RLD.P Roles for non-specific derivatives from patents: BIOL  
(Biological  
study); PREP (Preparation); PROC (Process); PRP (Properties);  
USES  
(Uses)  
RL.NP Roles from non-patents: ANST (Analytical study); BIOL  
(Biological  
study); OCCU (Occurrence); PREP (Preparation); PROC (Process);  
PRP  
(Properties); RACT (Reactant or reagent); USES (Uses)



SET NOTICE 1 DISPLAY  
SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 08:04:44 ON 06 JUL 2009  
L20 1 S 132539-06-1/RN  
L20 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 132539-06-1 REGISTRY  
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-  
(CA INDEX NAME)  
OTHER NAMES:  
CN Lanzac  
CN LY 170053  
CN Olanzapine  
CN Oleanz  
CN Oliza  
CN Oltal  
CN Zyprexa  
DR 1034315-19-9  
MF C17 H20 N4 S

CI COM  
 SR US Adopted Names Council (USAN)  
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS,  
 BIOTECHNO,  
 CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU,  
 EMBASE,  
 IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH,  
 IPA,  
 MEDLINE, MRCK\*, PATDPASPC, PHAR, PIRA, PROMT, PROUSDDR, PS,  
 RTECS\*,  
 SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL  
 (\*File contains numerically searchable property data)  
 DT.CA CAplus document type: Conference; Dissertation; Journal; Patent  
 RL.P Roles from patents: ANST (Analytical study); BIOL (Biological  
 study);  
 FORM (Formation, nonpreparative); PREP (Preparation); PROC  
 (Process);  
 PRP (Properties); PRPH (Prophetic); RACT (Reactant or reagent);  
 USES  
 (Uses)  
 RLD.P Roles for non-specific derivatives from patents: BIOL  
 (Biological  
 study); FORM (Formation, nonpreparative); PREP (Preparation); PRP  
 (Properties); RACT (Reactant or reagent); USES (Uses)  
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL  
 (Biological  
 study); MSC (Miscellaneous); OCCU (Occurrence); PREP  
 (Preparation); PROC  
 (Process); PRP (Properties); RACT (Reactant or reagent); USES  
 (Uses)  
 RLD.NP Roles for non-specific derivatives from non-patents: BIOL  
 (Biological  
 study); FORM (Formation, nonpreparative); PREP (Preparation);  
 PROC  
 (Process); RACT (Reactant or reagent)




SET NOTICE 1 DISPLAY  
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 08:05:12 ON 06 JUL 2009  
 L21 1 S 288-32-4/RN  
 SET NOTICE 1 DISPLAY  
 SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 08:05:30 ON 06 JUL 2009  
L22 1 S 362665-56-3/RN

L22 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 362665-56-3 REGISTRY  
CN Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]- (CA INDEX  
NAME)  
OTHER NAMES:  
CN 1-[3-[3-(4-Chlorophenyl)propoxy]propyl]piperidine  
CN 3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether  
CN Pitolisant  
MF C17 H26 Cl N O  
CI COM  
SR CA  
LC STN Files: ADISINSIGHT, CA, CAPLUS, CASREACT, IMSDRUGNEWS,  
IMSRESEARCH,  
PROUSDDR, SYNTHLINE, TOXCENTER, USAN, USPATFULL  
DT.CA CAplus document type: Journal; Patent  
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation);  
RACT  
(Reactant or reagent); USES (Uses)  
RLD.P Roles for non-specific derivatives from patents: BIOL  
(Biological  
study); USES (Uses)  
RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses)



SET NOTICE 1 DISPLAY  
SET NOTICE LOGIN DISPLAY

FILE 'CAPLUS' ENTERED AT 08:06:52 ON 06 JUL 2009  
L23 10 S L22  
L24 1 S L23 AND (PY<2003 OR AY<2003 OR PRY<2003)  
L25 9189 S L16-L20  
L26 2 S L23 AND L25

L26 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN  
TI Preparation of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine monohydrochloride as a histamine H3 receptor ligand.  
ACCESSION NUMBER: 2006:817672 CAPLUS Full-text  
DOCUMENT NUMBER: 145:249105  
TITLE: Preparation of  
1-[3-[3-(4-  
chlorophenyl)propoxy]propyl]piperidine  
monohydrochloride as a histamine H3 receptor  
ligand.  
INVENTOR(S): Raga, Manuel, M.; Sallares, Juan; Guerrero,  
Marta;  
Guglietta, Antonio  
PATENT ASSIGNEE(S): Ferrer Internacional, S. A., Spain  
SOURCE: PCT Int. Appl., 45pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
---	---	-----	-----	-----
WO 2006084833 20060206	A1	20060817	WO 2006-EP50703	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

L26 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN  
TI New psychiatric drug formulation with an antipsychotic or  
antidepressant  
and an histamine H3 receptor antagonist for the prevention of  
psychotropic  
adverse effects  
ACCESSION NUMBER: 2005:589 CAPLUS Full-text  
DOCUMENT NUMBER: 142:79960  
TITLE: New psychiatric drug formulation with an  
antipsychotic  
or antidepressant and an histamine H3 receptor  
antagonist for the prevention of psychotropic  
adverse  
effects  
INVENTOR(S): Schwartz, Jean Charles; Rousseau Lecomte,  
Jeanne Marie  
PATENT ASSIGNEE(S): Bioprojet, Fr.  
SOURCE: Fr. Demande, 32 pp.  
CODEN: FRXXBL  
DOCUMENT TYPE: Patent  
LANGUAGE: French  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

FR 2856596 20030627	A1	20041231	FR 2003-7836
FR 2856596 CA 2530381	B1	20070427	
20040625	A1	20050106	CA 2004-2530381
WO 2005000315	A1	20050106	WO 2004-FR1628
20040625			
CH, GD, LC, NI, SY, ZW	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, DK, SE, NE,		
	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, SN, TD, TG		

L27	0 S L26 AND (PY<2003 OR AY<2003 OR PRY<2003)
L28	2840 S L20
L29	85 S L20 AND HISTAMINE?
L30	152 S L20 AND ?HISTAMINE?
L31	41 S L30 AND (PY<2003 OR AY<2003 OR PRY<2003)

L31 ANSWER 10 OF 41 CAPLUS COPYRIGHT 2009 ACS on STN  
 TI Substance to prevent or reverse weight gain induced by psychoactive agents  
 ACCESSION NUMBER: 2003:396456 CAPLUS Full-text  
 DOCUMENT NUMBER: 138:379255  
 TITLE: Substance to prevent or reverse weight gain  
 induced by psychoactive agents  
 INVENTOR(S): Miller, Jon M.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 5 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

---

US 20030096808 A1 20030522 US 1999-280279

19990329 <--

PRIORITY APPLN. INFO.: US 1999-280279

19990329 <--

AB A substance to prevent or reverse weight gain induced by psychoactive agents comprises an antipsychotic drug or mood stabilizing drug in a concentration from 0.01% to 99.99% in combination with a histamine H<sub>2</sub>-receptor antagonist in a concentration from 99.99% to 0.01%. Example antipsychotic drugs are olanzapine, clozapine, risperidone, and quetiapine. The antipsychotic drug is typically in a concentration of 10% to 90%, 30% to 60% and 50%. Example mood stabilizing drugs are divalproex sodium, valproic acid, and mirtazapine. The mood stabilizing drug is typically in a concentration of 10% to 90%, 30% to 60% and 50%. Example histamine H<sub>2</sub>-receptor antagonist are nizatidine, famotidine, cimetidine and ranitidine. The histamine H<sub>2</sub>-receptor antagonist (16) is typically in a concentration of 60% to 30% and 50%.

IC ICM A61K031-551

L31 ANSWER 24 OF 41 CAPLUS COPYRIGHT 2009 ACS on STN  
TI Bodyweight gain with atypical antipsychotics: A comparative review  
ACCESSION NUMBER: 2001:141908 CAPLUS Full-text  
DOCUMENT NUMBER: 135:161867  
TITLE: Bodyweight gain with atypical antipsychotics: A comparative review  
AUTHOR(S): Wetterling, Tilman  
CORPORATE SOURCE: Department of Psychiatry and Psychotherapy,  
Johann  
SOURCE: Wolfgang Goethe University, Frankfurt, Germany  
Drug Safety (2001), 24(1), 59-73  
CODEN: DRSAEA; ISSN: 0114-5916  
PUBLISHER: Adis International Ltd.  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English

AB A review with 93 refs. The atypical antipsychotics have been shown to have superior efficacy compared with typical antipsychotics such as haloperidol, particularly in the treatment of neg. symptoms of schizophrenia. Furthermore, they induce less extrapyramidal effects. However, following clin. use, marked bodyweight gain has been frequently observed with some of the atypical antipsychotic drugs. In order to examine and compare the frequency, amount and conditions of bodyweight gain during treatment with atypical antipsychotics, studies concerning bodyweight gain with these agents were identified through a MEDLINE search from 1966 to Mar. 2000. Although comparison is limited by the different designs and recruitment procedures of the reviewed studies, the available data support the notion that the frequency as well as the amount of bodyweight gain is high in patients treated with olanzapine (average bodyweight gain 2.3 kg/mo), clozapine (1.7 kg/mo), quetiapine (1.8 kg/mo), and possibly also zotepine (2.3 kg/mo). Moderate changes in bodyweight have been observed in the treatment with risperidone (average bodyweight gain 1.0 kg/mo). Ziprasidone seems to induce only slight bodyweight changes (0.8 kg/mo). Bodyweight gain most frequently occurs in the first 12 wk of treatment. Patients who

were underweight at the beginning of treatment are at highest risk, of gaining bodyweight. The underlying pathomechanism still remains largely unclear. The relative receptor affinities of the atypical antipsychotics for histamine H1 receptors as well as the ratio of their affinity for serotonin 5-HT2 and dopamine D2 receptors appear to be the most robust correlate of bodyweight gain. Furthermore, the induction of leptin secretion may have an important impact on bodyweight gain in patients treated with atypical antipsychotics. Although many questions concerning the pathogenesis of bodyweight gain remain unresolved, this adverse effect has to be taken into consideration when prescribing the atypical antipsychotics, particularly in view its affect on compliance during long term treatment and the long term effects of obesity on mortality and morbidity.

L31 ANSWER 26 OF 41 CAPLUS COPYRIGHT 2009 ACS on STN  
TI Combination for treating weight gain associated with antipsychotic use  
comprising an atypical antipsychotic and an H2 antagonist  
ACCESSION NUMBER: 2000:881023 CAPLUS Full-text  
DOCUMENT NUMBER: 134:33017  
TITLE: Combination for treating weight gain associated with  
antipsychotic use comprising an atypical antipsychotic  
and an H2 antagonist  
INVENTOR(S): Todd, Jane Rogers  
PATENT ASSIGNEE(S): Eli Lilly and Company, USA  
SOURCE: PCT Int. Appl., 43 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
---				
WO 2000074784	A1	20001214	WO 2000-US9811	
20000522 <--				
CR,	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN,			
HU,	CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,			
LU,	ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,			
SE,	LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,			
ZA, ZW	SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,			
CY,	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH,			
BJ,	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF,			
	CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1189662	A1	20020327	EP 2000-931932	
20000522 <--				

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,  
PT,  
IE, SI, LT, LV, FI, RO

L31 ANSWER 29 OF 41 CAPLUS COPYRIGHT 2009 ACS on STN  
TI H2 antagonist nizatidine may control olanzapine-associated weight  
gain in

schizophrenic patients

ACCESSION NUMBER: 2000:489015 CAPLUS Full-text

DOCUMENT NUMBER: 134:13255

TITLE: H2 antagonist nizatidine may control  
olanzapine-associated weight gain in  
schizophrenic

patients

AUTHOR(S): Sacchetti, E.; Guarneri, L.; Bravi, D.

CORPORATE SOURCE: University Psychiatric Service, University  
School of

Medicine & Spedali Civili, Brescia, Italy

SOURCE: Biological Psychiatry (2000), 48(2), 167-168

CODEN: BIPCBF; ISSN: 0006-3223

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Background: Olanzapine is temporally associated, in a number of patients with schizophrenia, with weight gain. H2 antagonists, like nizatidine, have been shown to control appetite in overweight patients. Methods: A patient with olanzapine temporally associated weight gain was treated with nizatidine as "add-on" therapy. Results: Nizatidine treatment was associated with good control and subsequent reduction of weight after 4 to 5 wk of therapy in a patient with repetitive episodes of weight gain during olanzapine treatment. Olanzapine was otherwise well tolerated and effective in controlling psychopathol. Conclusions: H2 antagonist treatment with olanzapine may be a valid medical strategy in preventing and/or reducing weight gain in patients with schizophrenia. Controlled studies are recommended to confirm this observation.

CC 1-11 (Pharmacology)

ST nizatidine histamine antagonist antobesity olanzapine  
schizophrenia

IT Antihistamines

(H2; H2 antagonist nizatidine may control olanzapine-associated  
weight gain

in schizophrenic humans)

IT 132539-06-1, Olanzapine

RL: ADV (Adverse effect, including toxicity); THU (Therapeutic  
use); BIOL

(Biological study); USES (Uses)

(H2 antagonist nizatidine may control olanzapine-associated  
weight gain in  
schizophrenic humans)

=> e schwartz jean?/au

E121 1 SCHWARTZ JEAN P/AU

E122 4 SCHWARTZ JEAN PIERRE/AU

```

E123      0 --> SCHWARTZ JEAN?/AU
E124      5 SCHWARTZ JEANNA/AU
E125      5 SCHWARTZ JEFF/AU
E126      2 SCHWARTZ JEFFERY/AU
E127      1 SCHWARTZ JEFFERY H/AU
E128      7 SCHWARTZ JEFFERY L/AU
E129      1 SCHWARTZ JEFFERY S/AU
E130      1 SCHWARTZ JEFFFREY/AU
E131      274 SCHWARTZ JEFFREY/AU
E132      1 SCHWARTZ JEFFREY A/AU

=> e lecomte jeanne?/au
E133      7 LECOMTE JEANNE M/AU
E134      72 LECOMTE JEANNE MARIE/AU
E135      0 --> LECOMTE JEANNE?/AU
E136      13 LECOMTE JEROME/AU
E137      1 LECOMTE JOAN/AU
E138      1 LECOMTE JOSEPH/AU
E139      1 LECOMTE JOULIN V/AU
E140      5 LECOMTE JULIE/AU
E141      2 LECOMTE JULIETTE/AU
E142      1 LECOMTE JULIETTE T/AU
E143      76 LECOMTE JULIETTE T J/AU
E144      1 LECOMTE JULIETTE THERESE J/AU

=> s e133-e134
      7 "LECOMTE JEANNE M"/AU
      72 "LECOMTE JEANNE MARIE"/AU
L32      79 ("LECOMTE JEANNE M"/AU OR "LECOMTE JEANNE MARIE"/AU)

=> s l32 and histamine?
      5 HISTIAMINE?
L33      0 L32 AND HISTIAMINE?

=> s l32 and (py<2003 or ay<2003 or pry<2003)
      22984276 PY<2003
      4508246 AY<2003
      3977805 PRY<2003
L34      62 L32 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> s l32 and l23
L35      5 L32 AND L23

=> s l35 and (py<2003 or ay,2003 or pry<2003)
      22984276 PY<2003
      3432 AY
      40 AYS
      3472 AY
          (AY OR AYS)
      44526 2003
      0 AY,2003
          (AY(W)2003)
      3977805 PRY<2003
L36      1 L35 AND (PY<2003 OR AY,2003 OR PRY<2003)

=> s l35 and (py<2003 or ay<2003 or pry<2003)
      22984276 PY<2003

```

4508246 AY<2003  
3977805 PRY<2003  
L37 1 L35 AND (PY<2003 OR AY<2003 OR PRY<2003)